Calamos Wealth Management LLC Has $3.41 Million Position in AbbVie Inc. $ABBV

Calamos Wealth Management LLC grew its stake in AbbVie Inc. (NYSE:ABBV) by 74.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,729 shares of the company’s stock after acquiring an additional 6,298 shares during the quarter. Calamos Wealth Management LLC’s holdings in AbbVie were worth $3,410,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Calamos Advisors LLC increased its stake in AbbVie by 0.3% in the third quarter. Calamos Advisors LLC now owns 450,832 shares of the company’s stock valued at $104,386,000 after purchasing an additional 1,214 shares in the last quarter. Single Point Partners LLC acquired a new position in shares of AbbVie in the 3rd quarter valued at $211,000. Brendel Financial Advisors LLC increased its position in shares of AbbVie by 248.4% in the 3rd quarter. Brendel Financial Advisors LLC now owns 22,908 shares of the company’s stock valued at $5,304,000 after buying an additional 16,333 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al raised its stake in AbbVie by 48.9% during the 3rd quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 293,111 shares of the company’s stock worth $67,867,000 after buying an additional 96,200 shares during the period. Finally, Sax Wealth Advisors LLC lifted its holdings in AbbVie by 20.2% during the third quarter. Sax Wealth Advisors LLC now owns 9,080 shares of the company’s stock worth $2,102,000 after acquiring an additional 1,526 shares in the last quarter. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ABBV. Hsbc Global Res upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a report on Wednesday, December 10th. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They set a “sector outperform” rating and a $280.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and issued a $289.00 price target (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. HSBC upgraded shares of AbbVie from a “hold” rating to a “buy” rating and upped their price target for the company from $225.00 to $265.00 in a report on Wednesday, December 10th. Finally, Wall Street Zen raised shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 13th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average price target of $245.84.

AbbVie Stock Performance

Shares of ABBV opened at $229.63 on Wednesday. The stock has a market capitalization of $405.84 billion, a price-to-earnings ratio of 173.96, a PEG ratio of 1.31 and a beta of 0.36. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a fifty day simple moving average of $226.67 and a 200 day simple moving average of $213.27. The company has a current ratio of 0.72, a quick ratio of 0.60 and a debt-to-equity ratio of 44.14.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same period in the previous year, the business earned $3.00 EPS. The company’s revenue was up 9.1% compared to the same quarter last year. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be issued a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a yield of 3.0%. AbbVie’s dividend payout ratio is currently 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.